Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    138
    ...
ATC Name B/G Ingredients Dosage Form Price
B05XA02 SODIUM BICARBONATE G Sodium bicarbonate - 4.2g/100ml 4.2g/100ml Injectable solution 742,370 L.L
D10BA01 CURACNE G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,603,204 L.L
G04BX14 PRIXETIN 60 G Dapoxetine (hydrochloride) - 60mg Tablet, film coated 1,479,123 L.L
J01DC02 CEFUMAX G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 159,917 L.L
J01MA12 LEVOFLOXACIN- HAMELN G Levofloxacin - 500mg/100ml 5mg/ml Injectable solution 1,632,769 L.L
L02BG06 EXEMESTANE PHARMINICIO G Exemestane - 25mg 25mg Tablet, film coated 1,158,392 L.L
M01AB15 KETOLAC G Ketorolac trometamine - 30mg/2ml 30mg/2ml Injectable solution 268,769 L.L
N01BB02 LIDOCAINE ARWAN G Lidocaine (HCl) - 1% 1% Injectable solution 1,995,158 L.L
N03AX09 LAMOTRIGINE ARROW LAB G Lamotrigine - 25mg 25mg Tablet, dispersible/ chewable 556,351 L.L
N05AX15 REAGILA G Cariprazine - 6mg 6mg Capsule, hard 6,394,003 L.L
P01AB01 METRO-SOLUTIONS G Metronidazole - 500mg/100ml 500mg/100ml Injectable solution 166,381 L.L
R05DB13 RAPICOD G Butamirate citrate - 0.15% 0.15% Syrup 296,989 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 500mg 500mg Tablet, film coated 193,513 L.L
A11DB NEURORUBINE-FORTE G Vitamin B12 - 1mg, Vitamin B6 - 50mg, Vitamin B1 - 200mg Tablet, film coated 262,049 L.L
B05XA02 SODIUM BICARBONATE G Sodium bicarbonate - 8.4g/100ml 8.4% Injectable solution 959,565 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 20mg 20mg Tablet, film coated 667,890 L.L
C10AB04 LOW-LIP G Gemfibrozil - 600mg 600mg Tablet, film coated 298,333 L.L
D10BA01 CURACNE G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,603,204 L.L
J01DC02 CEFUROXIME – PANPHARMAPOUDRE POUR SOLUTION INJ. IM/IV G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 3,922,676 L.L
J01MA12 LEVOFLOXACIN NORMON G Levofloxacin - 500mg/100ml 5mg/ml Injectable solution 27,147,388 L.L
N01BB02 ? 1% LIDOCAINE HCL USP G Lidocaine HCl - 1% 1% Injectable solution 76,791 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 25mg 25mg Tablet, dispersible 595,322 L.L
P01AB01 POLGYL G Metronidazole - 0.5% 0.5% Injectable solution 134,384 L.L
R05DB13 TUSSIN G Butamirate citrate - 7.5mg/5ml 7.5mg/5ml Syrup, sugar free 296,925 L.L
L04AX05 PULMOFIB 267 G Pirfenidone - 267mg 267mg Tablet, film coated L.L
A11DB TRILAGAVIT G Vitamin B12 - 1mg, Vitamin B6 - 100mg, Vitamin B1 - 200mg Tablet, film coated 399,121 L.L
B05XA02 SODIUM BICARBONATE G Sodium bicarbonate - 1.4g/100ml 1.4g/100ml Injectable solution 258,887 L.L
C05CX GINKGO BIOGARAN G Ginkgo biloba extract - 40mg 40mg Tablet, coated 345,368 L.L
C10AB05 FENOFIBRATE ARROW G Fenofibrate - 145mg 145mg Tablet, film coated 639,669 L.L
D10BA01 CURACNE G Isotretinoin - 5mg 5mg Capsule, soft gelatin 856,028 L.L
    ...
    138
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026